BRPI0913475A2 - Molécula de ácido nucleico, vetor, célula, método para proteção de uma célula, métodos para expressão de uma proteína de interesse, método para adição ou intensificação da adaptabilidade ou resistência de uma célula e kit - Google Patents

Molécula de ácido nucleico, vetor, célula, método para proteção de uma célula, métodos para expressão de uma proteína de interesse, método para adição ou intensificação da adaptabilidade ou resistência de uma célula e kit

Info

Publication number
BRPI0913475A2
BRPI0913475A2 BRPI0913475-1A BRPI0913475A BRPI0913475A2 BR PI0913475 A2 BRPI0913475 A2 BR PI0913475A2 BR PI0913475 A BRPI0913475 A BR PI0913475A BR PI0913475 A2 BRPI0913475 A2 BR PI0913475A2
Authority
BR
Brazil
Prior art keywords
cell
expressing
kit
protecting
vector
Prior art date
Application number
BRPI0913475-1A
Other languages
English (en)
Inventor
Laetitia Malphettes
Andrew Snowden
Inn H Yuk
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0913475A2 publication Critical patent/BRPI0913475A2/pt
Publication of BRPI0913475B1 publication Critical patent/BRPI0913475B1/pt
Publication of BRPI0913475B8 publication Critical patent/BRPI0913475B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
BRPI0913475A 2008-09-15 2009-09-15 vetor BRPI0913475B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9714908P 2008-09-15 2008-09-15
US61/097,149 2008-09-15
PCT/US2009/057031 WO2010031074A2 (en) 2008-09-15 2009-09-15 Compositions and methods for regulating cell osmolarity

Publications (3)

Publication Number Publication Date
BRPI0913475A2 true BRPI0913475A2 (pt) 2015-08-04
BRPI0913475B1 BRPI0913475B1 (pt) 2019-04-16
BRPI0913475B8 BRPI0913475B8 (pt) 2019-05-07

Family

ID=42005828

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913475A BRPI0913475B8 (pt) 2008-09-15 2009-09-15 vetor

Country Status (16)

Country Link
US (3) US20110269233A1 (pt)
EP (1) EP2326720B1 (pt)
JP (4) JP5524214B2 (pt)
KR (5) KR20150126739A (pt)
CN (2) CN102216459A (pt)
AU (1) AU2009290563A1 (pt)
BR (1) BRPI0913475B8 (pt)
CA (1) CA2734922C (pt)
ES (1) ES2670368T3 (pt)
HK (1) HK1199906A1 (pt)
HR (1) HRP20180738T1 (pt)
IL (1) IL211368B (pt)
MX (2) MX2011002638A (pt)
PL (1) PL2326720T3 (pt)
SI (1) SI2326720T1 (pt)
WO (1) WO2010031074A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2734922C (en) * 2008-09-15 2020-01-14 Genentech, Inc. Compositions comprising polynucleotides comprising hybrid osmo-responsive transcriptional regulatory elements and methods for producing a protein under conditions of hyperosmolarity
AU2010306377B2 (en) 2009-10-13 2015-01-22 Stemcell Technologies Canada Inc. Manipulation of osmolality for differentiating stem cells
US9708582B2 (en) * 2009-10-13 2017-07-18 Stemcell Technologies Inc. Method of differentiating stem cells
PL2576580T3 (pl) * 2010-05-28 2017-03-31 F.Hoffmann-La Roche Ag Zmniejszenie poziomu mleczanu i zwiększenie wytwarzania polipeptydu przez obniżenie poziomu ekspresji dehydrogenazy mleczanowej i kinazy dehydrogenazy pirogronianowej
CA2829774C (en) * 2011-03-14 2019-09-24 National Research Council Of Canada Method of viral production in cells
CA2838695C (en) 2011-07-01 2017-02-14 Amgen Inc. Mammalian cell culture
JP2015521863A (ja) * 2012-07-13 2015-08-03 エル． ホルツマン，ジョーダン アルツハイマー病の治療のための治療薬剤をスクリーニングするための細胞モデルと動物モデル
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
EP3555320B1 (en) 2016-12-19 2021-10-27 DuPont Nutrition Biosciences ApS Methods and strain
US10640766B2 (en) 2017-04-12 2020-05-05 Tempo Bioscience, Inc. Biosensors for chloride ions
US10571480B2 (en) 2017-04-12 2020-02-25 Tempo Bioscience, Inc. Biosensors for cellular osmolarity
IL270467B2 (en) * 2017-06-16 2025-05-01 Lonza Ag A universal self-control platform for a mammalian cell line for the preparation of biological materials
EP4036238A1 (en) * 2021-01-27 2022-08-03 The University Court of the University of Edinburgh Functional nucleic acid molecule and method
IL314004A (en) * 2022-01-04 2024-08-01 Ronawk Inc A genetically reprogrammed extracellular matrix
CN115299264B (zh) * 2022-09-02 2023-12-19 福建农林大学 正癸烷在促进杉木生长中的应用和方法

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US5087571A (en) 1984-06-22 1992-02-11 President And Fellows Of Harvard College Method for providing a cell culture from a transgenic non-human mammal
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5573933A (en) 1987-04-14 1996-11-12 Luminis Pty, Ltd. Transgenic pigs
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US5602244A (en) 1988-05-26 1997-02-11 Competitive Technologies, Inc. Polynucleotide phosphorodithioate compounds
ATE131872T1 (de) 1989-11-22 1996-01-15 Genentech Inc Latenz assoziierte peptide und deren verwendung
ES2217250T3 (es) 1990-06-15 2004-11-01 Scios Inc. Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
US5270192A (en) 1991-02-07 1993-12-14 Monsanto Company Biological artificial liver
US6110700A (en) 1991-03-11 2000-08-29 The General Hospital Corporation PRAD1 cyclin and its cDNA
US5922854A (en) 1991-06-14 1999-07-13 Kumar; Ramesh Purifying Human Hemogloblin from transgenic pig red cells and plasmids containing pig globin nucleic acids
US5747341A (en) 1991-06-24 1998-05-05 Pacific Biomedical Research, Inc. Culture media having low osmolarity for establishing and maintaining hormone-secreting cells in long-term culture
US5300687A (en) 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
US6001982A (en) 1993-07-29 1999-12-14 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US5639940A (en) 1994-03-03 1997-06-17 Pharmaceutical Proteins Ltd. Production of fibrinogen in transgenic animals
NZ281041A (en) 1994-03-09 1998-04-27 Abbott Lab Non-human mammals transformed with a catalytic entity of enzymes or antibodies to produce a heterologous product in the animals milk
NZ279676A (en) 1994-03-09 1998-04-27 Abbott Lab Humanized milk produced by non-human transgenic mammal transformed with a heterologous gene coding for human enzyme producing human oligosaccharides and glycoconjugates
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5750870A (en) 1994-06-17 1998-05-12 Agritope, Inc. Plant genetic transformation methods and transgenic plants
US5959171A (en) 1994-08-17 1999-09-28 Pharming B.V. Method for the production of biologically active polypeptides in a mammal's
EP0778886A4 (en) 1994-09-01 2001-05-02 TRANSGENIC ANIMAL WHICH EXPRESSES A FAMILY FORM OF THE HUMAN AMYLOID FOREQUARTER PROTEIN
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
US5880327A (en) 1994-09-21 1999-03-09 American National Red Cross Transgenic mammals expressing human coagulation factor VIII
US6187992B1 (en) 1994-12-05 2001-02-13 Merck & Co., Inc. Transgenic mouse having a disrupted amyloid precursor protein gene
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US5962674A (en) 1995-06-01 1999-10-05 Hybridon, Inc. Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
EP0831854A4 (en) 1995-06-06 2001-01-24 Isis Pharmaceuticals Inc OLIGONUCLEOTIDS WITH PHOSPHOROTHIOATE BINDINGS OF HIGH CHIRAL PURITY
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US5734041A (en) 1995-10-20 1998-03-31 Mcgill University Preparation of chiral phosphorothioate oligomers
US5965125A (en) 1995-10-25 1999-10-12 Transkaryotic Therapies, Inc. Hybrid matrix implants and explants
US5721118A (en) 1995-10-31 1998-02-24 The Regents Of The University Of California, San Diego Mammalian artificial chromosomes and methods of using same
AR005035A1 (es) 1995-12-11 1999-04-07 Merck Patent Ges Mit Beschränkter Haftung Procedimiento para preparar proteinas recombinantes en e. coli, mediante fermentacion con gran concentracion de celulas.
US6025155A (en) 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6933331B2 (en) 1998-05-22 2005-08-23 Nanoproducts Corporation Nanotechnology for drug delivery, contrast agents and biomedical implants
CA2251263A1 (en) 1997-11-14 1999-05-14 Hajime Karasuyama Transgenic animal allergy models and methods for their use
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6886568B2 (en) 1998-04-08 2005-05-03 The Johns Hopkins University Method for fabricating cell-containing implants
US6156952A (en) 1998-04-09 2000-12-05 Constituent Institution Of The University Of Maryland System HIV transgenic animals and uses therefor
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US6511824B1 (en) 1999-03-17 2003-01-28 Exelixis, Inc. Nucleic acids and polypeptides of invertebrate TWIK channels and methods of use
CA2384880C (en) * 1999-09-27 2010-09-21 Genentech, Inc. Methods for making recombinant proteins using apoptosis inhibitors
US6531644B1 (en) 2000-01-14 2003-03-11 Exelixis, Inc. Methods for identifying anti-cancer drug targets
US6515109B1 (en) 2000-10-12 2003-02-04 Exelixis, Inc. Human ECT2 polypeptide
US7198940B2 (en) 2000-10-25 2007-04-03 Shot Hardware Optimization Technology, Inc. Bioreactor apparatus and cell culturing system
WO2002040697A2 (en) 2000-11-03 2002-05-23 Genentech, Inc. Metabolic rate shifts in fermentations expressing recombinant proteins
KR100350216B1 (ko) * 2001-02-02 2002-08-28 (주)제노마인 삼투 스트레스 신호 전달 경로에서 억제 조절 작용을 하는 삼투 스트레스에 의해 유도되는 단백질
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
WO2002088332A1 (en) 2001-04-24 2002-11-07 Hokkaido Technology Licensing Office Co.,Ltd. Small liver cell-rich colony, method of preparing the same, method of maturing the same into liver tissue and method of estimating drug function using the matured small liver cell-rich colony
ATE535604T1 (de) 2002-01-18 2011-12-15 Silbiotec Due Sa Immobilisierung von biologischen materials in einem silikatischen schicht
AU2003217700A1 (en) 2002-02-26 2003-09-09 Stelsys Llc Hepatocyte bioreactor system for long term culture of functional hepatocyte spheroids
US7348175B2 (en) 2002-03-15 2008-03-25 St3 Development Corporation Bioreactor with plurality of chambers for conditioning intravascular tissue engineered medical products
US7166133B2 (en) 2002-06-13 2007-01-23 Kensey Nash Corporation Devices and methods for treating defects in the tissue of a living being
WO2004050823A1 (en) 2002-12-02 2004-06-17 Council Of Scientific And Industrial Research Porous vessel bioreactor
ITMO20030081A1 (it) 2003-03-21 2004-09-22 Rand Srl Bioreattore, particolarmente per organi bioartificiali.
US7241455B2 (en) 2003-04-08 2007-07-10 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing radiation-crosslinked polymer for controlled delivery of a therapeutic agent
WO2005001067A1 (en) 2003-05-27 2005-01-06 Frederick Blattner Animal bioreactors
EP1648298A4 (en) 2003-07-25 2010-01-13 Dexcom Inc OXYGEN-IMPROVED MEMBRANE SYSTEMS FOR IMPLANTABLE DEVICES
US7794706B2 (en) 2003-10-14 2010-09-14 Medivas, Llc Bioactive wound dressings and implantable devices and methods of use
DE10358400A1 (de) 2003-12-11 2005-07-07 Linde-Kca-Dresden Gmbh Verfahren und Vorrichtung zur biologischen Behandlung einer Suspension in einem Bioreaktor mit integrierter hydraulischer Sinkschichtentnahme
JP2007515958A (ja) 2003-12-19 2007-06-21 ユニヴァーシティー オブ ウォータールー 培養細胞、細胞培養の方法および機器
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US7951555B2 (en) 2004-05-18 2011-05-31 Australian Nuclear Science And Technology Organisation Membrane bioreactor
US20080044890A1 (en) 2004-06-30 2008-02-21 Parker Clayton R Interchangable sleeve for enhancing proliferation of cells in a rotating bioreactor
US7156985B1 (en) 2004-07-16 2007-01-02 Shaw Intellectual Property Holdings, Inc. Bioreactor system having improved temperature control
EP1796693A2 (en) 2004-08-26 2007-06-20 Chandrashekhar P. Pathak Implantable tissue compositions and method
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US7351423B2 (en) 2004-09-01 2008-04-01 Depuy Spine, Inc. Musculo-skeletal implant having a bioactive gradient
WO2006080009A2 (en) 2005-01-25 2006-08-03 Nicast Ltd. Implantable bioreactors and uses thereof
US7759120B2 (en) 2005-03-02 2010-07-20 Kps Bay Medical, Inc. Seeding implantable medical devices with cells
US7264962B1 (en) 2005-03-14 2007-09-04 Sandia Corporation Enzymatic cascade bioreactor
WO2007025008A2 (en) * 2005-08-24 2007-03-01 The Scripps Research Institute Translation enhancer-element dependent vector systems
US20070231901A1 (en) 2005-12-02 2007-10-04 Shuichi Takayama Microfluidic cell culture media
US20080057571A1 (en) 2006-04-28 2008-03-06 North Carolina State University Bioreactor device for exposing a cell culture to a fluid shear force imparted by a fluid flow
TW200743669A (en) 2006-05-18 2007-12-01 Nat Defense University Chung Cheng Inst Of Technology Bioreactor capable of producing uniform shear stress distribution
US7851204B2 (en) 2006-06-09 2010-12-14 Pall Microreactor Technologies, Inc. Closure for milliliter scale bioreactor
CN1884131B (zh) 2006-06-28 2010-05-12 深圳市金达莱环保股份有限公司 复合曝气式膜生物反应器
US9023642B2 (en) 2006-07-07 2015-05-05 The University Of Houston System Method and apparatus for a miniature bioreactor system for long-term cell culture
US8008065B2 (en) 2006-08-02 2011-08-30 Finesse Solutions, Llc. Disposable bioreactor vessel port
US20080032396A1 (en) 2006-08-02 2008-02-07 Becton, Dickinson And Company Bioreactor and Method
US7378023B2 (en) 2006-09-13 2008-05-27 Nalco Company Method of improving membrane bioreactor performance
US7290669B1 (en) 2006-10-27 2007-11-06 Utah State University Upflow bioreactor having a septum and an auger and drive assembly
US20080119909A1 (en) 2006-11-21 2008-05-22 Neurotrophincell Pty Limited Cell implantation to prevent and/or treat hearing loss
KR20080051337A (ko) * 2006-12-05 2008-06-11 부산대학교 산학협력단 스트레스－유도적 프로모터 및 제아잔틴 에폭시데이즈유전자가 도입되어 있는 스트레스 저항성 식물체
CA2734922C (en) 2008-09-15 2020-01-14 Genentech, Inc. Compositions comprising polynucleotides comprising hybrid osmo-responsive transcriptional regulatory elements and methods for producing a protein under conditions of hyperosmolarity

Also Published As

Publication number Publication date
US10100319B2 (en) 2018-10-16
US20110269233A1 (en) 2011-11-03
JP2018157825A (ja) 2018-10-11
JP6342863B2 (ja) 2018-06-13
CA2734922A1 (en) 2010-03-18
MX2011002638A (es) 2011-04-05
US20150307888A1 (en) 2015-10-29
MX347112B (es) 2017-04-12
PL2326720T3 (pl) 2018-08-31
US20190127741A1 (en) 2019-05-02
JP2016028585A (ja) 2016-03-03
KR20110056323A (ko) 2011-05-26
ES2670368T3 (es) 2018-05-30
US11279939B2 (en) 2022-03-22
CA2734922C (en) 2020-01-14
WO2010031074A3 (en) 2010-07-01
KR101880919B1 (ko) 2018-07-24
EP2326720A2 (en) 2011-06-01
IL211368B (en) 2021-12-01
EP2326720A4 (en) 2012-04-18
AU2009290563A1 (en) 2010-03-18
KR20160104105A (ko) 2016-09-02
KR102018475B1 (ko) 2019-09-04
EP2326720B1 (en) 2018-03-21
JP5524214B2 (ja) 2014-06-18
BRPI0913475B8 (pt) 2019-05-07
JP2012502630A (ja) 2012-02-02
JP2014168470A (ja) 2014-09-18
CN102216459A (zh) 2011-10-12
CN103937797B (zh) 2021-09-21
KR20130099255A (ko) 2013-09-05
WO2010031074A2 (en) 2010-03-18
JP6797151B2 (ja) 2020-12-09
IL211368A0 (en) 2011-04-28
HRP20180738T1 (hr) 2018-06-15
CN103937797A (zh) 2014-07-23
KR20150126739A (ko) 2015-11-12
BRPI0913475B1 (pt) 2019-04-16
KR20180085055A (ko) 2018-07-25
JP5809314B2 (ja) 2015-11-10
SI2326720T1 (en) 2018-06-29
HK1199906A1 (en) 2015-07-24

Similar Documents

Publication Publication Date Title
BRPI0913475A2 (pt) Molécula de ácido nucleico, vetor, célula, método para proteção de uma célula, métodos para expressão de uma proteína de interesse, método para adição ou intensificação da adaptabilidade ou resistência de uma célula e kit
EP3699291C0 (en) METHODS FOR ANALYZING UNIQUE NUCLEIC ACID SEQUENCE AND COMPOSITIONS
BRPI0922187A2 (pt) composição vetor, kit para a montagem de um polinucleotídeo, biblioteca de moléculas de ácido nucleico, métodos para gerar um polinucleotídeo, e uma célula hospedeira, célula hospedeira, polinucleotídeo, e , método para fabricar um vetor
BRPI0909212A2 (pt) Composições e método para sequeciamento de ácido nucléico
BRPI1006368A2 (pt) proteína de fusão. molécula de ácido nucleico, vetor, célula modificada geneticamente, método para produção da proteína de fusão, usos da proteína de fusão, composição, método para preparação de uma composição, kits, método e uso da proteína de fusão
BRPI0813242A2 (pt) Proteína de ligação a antígeno isolada, ácido nucléico isolado, vetor, célula hospedeira isolada, método para a produção de uma proteína de ligação a antígeno, e, composição.
BRPI0909044A2 (pt) anticorpo, sequência de ácidos nucleicos, vetor, composição farmacêutica, kit de partes, e, uso de um anticorpo, uma sequência de ácidos nucléicos, um vetor, uma composição farmacêutica ou um kit de partes
BR112012024287A2 (pt) anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira
BR112012006326A2 (pt) anticorpo biespecífico, composição farmacêutica, sequência de ácidos nucleicos, vetor de expressão, célula hospedeira procariótica ou eucariótica e invenção
GB0922209D0 (en) Proteins, nucleic acid molecules and compositions
ZA201102252B (en) Methods and kits for nucleic acid sequencing
BRPI0814781A2 (pt) Proteína, sequência de ácido nucleico, método para a produção de ácido itacônico, vetor, célula hospedeira, e, uso de um ácido cis-aconítico
EP2126072A4 (en) MATERIALS AND METHOD FOR THE INDIVIDUAL MOLECULE SEQUENCING OF NUCLEIC ACIDS
BR112012031843A2 (pt) molécula de peptídeo, molécula de ácido nucleico, vetor, célula hospedeira, método de produção de peptídeo, composição, método de produção da composição, método de detecção do comportamento de internalização do peptídeo, composição farmacêutica, uso do peptídeo, método para a prevenção e/ou tratamento e kit de partes
DK2086576T3 (da) H5-proteiner, nukleinsyremolekyler og vektorer kodende for disse, samt medicinsk anvendelse heraf
BRPI0906241A2 (pt) Molécula de ácido nucléico isolada, gene quimérico, vetor e método de transformação de uma célula bacteriana.
BRPI0812446A2 (pt) Métodos para aperfeiçoamento de propriedades de proteína múltiplas
DK2282764T3 (da) Leverspecifikke nukleinsyreregulerende elementer samt fremgangsmåder og anvendelser heraf
EP2200657A4 (en) IMPROVED METHODS AND COMPOSITIONS FOR F-18 MARKING PROTEINS, PEPTIDES, AND OTHER MOLECULES
EP1999276A4 (en) METHOD AND AGENT FOR NUCLEIC ACID SEQUENCING
DK2227330T3 (da) Mobilt hurtigtestsystem til nukleinsyreanalyse
BRPI0908625A2 (pt) método de inibir a entrada de uma proteína efetora patogênica em uma célula, método de identificar proteínas efetoras patogênicas, método para a leitura de compostos e método para prever se um gene em um genoma de um patógeno codifica ou não uma molécula efetora patogênica
EP2254897A4 (en) METHOD, REAGENTS AND KITS FOR DETECTING NUCLEIC ACID MOLECULES
EP2276860A4 (en) METHOD FOR THE IDENTIFICATION OF THE SEQUENCE OF ONE OR MORE VARIANTIC NUCLEOTIDES IN A NUCLEIC ACID MOLECULE
FI20085039L (fi) Nukleiinihappokoettimia ja laaja-alaisia alukkeita

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/09/2009, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/09/2009, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/09/2009, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2519 DE 16/04/2019,QUANTO AO ENDERECO DO DEPOSITANTE.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2845 DE 15-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.